Researchers have a gentle warning for patients on the receiving end of 765,000 prescriptions for the weight-loss drug Contrave: The cardiovascular safety of this treatment "remains uncertain," they write in a newly published study.
As for claims by the drug's maker that it dramatically drives down...
via L.A. Times - Science http://ift.tt/1R4qqYs
No comments:
Post a Comment